# Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD

> **NCT01387230** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 206 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** GSK573719
- **DRUG:** GSK573719
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01387230
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07-01
- **Primary completion:** 2012-02-01
- **Final completion:** 2012-02-13
- **Target enrollment:** 206 (ACTUAL)
- **Last updated:** 2017-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01387230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01387230, "Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01387230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*